SEARCH

SEARCH BY CITATION

References

  • 1
    Pemberton JH, Kelly KA, Beart RW, et al. Ileal pouch-anal anastomosis for chronic ulcerative colitis. Long-term results. Ann Surg 1987; 206: 504 13.
  • 2
    Nicholls RJ, Moskowitz RL, Shepherd NA. Restorative proctocolectomy with ileal reservoir. Br J Surg 1985; 72: S76S76.
  • 3
    Shepherd NA, Hulten L, Tytgat GNJ, et al. Workshop: pouchitis. Int J Colorectal Dis 1989; 4: 205 29.
  • 4
    Penna C, Dozois R, Tremaine W, et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996; 38: 234 9.
  • 5
    Svaninger G, Nordgren S, Oresland T, Hulten L. Incidence and characteristics of pouchitis in the Kock continent, ileostomy and the pelvic pouch. Scan J Gastroenterol 1993; 28: 695 700.
  • 6
    Nicholls RJ, Chir M, Banerjee, et al. Pouchitis: risk factors, etiology and treatment. World J Surg 1998; 22: 347 51.
  • 7
    Sagar PM & Pemberton JH. Ileo-anal pouch function and dysfunction. Dig Dis 1997; 15: 172 88.
  • 8
    Keighley MRB. Review article: the management of pouchitis. Aliment Pharmacol Ther 1996; 10: 449 57.
  • 9
    Sandborn WJ. Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology 1994; 107: 1856 60.
  • 10
    Madden M, McIntyre A, Nicholls RJ. Double blind cross-over trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci 1994; 39: 1193 6.
  • 11
    Sandborn WJ, Tremaine WJ, Batts KP, et al. Pouchitis following ileal pouch-anal anastomosis: a pouchitis disease activity index. Mayo Clin Proc 1994; 69: 409 15.
  • 12
    Descombe JJ, Dubourg D, Picard M, Palazzini E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharm Res 1994; 14: 51 6.
  • 13
    Kmiot WA, Youngs D, Tudor R, et al. Mucosal morphology, cell proliferation and faecal bacteriology in acute pouchitis. Br J Surg 1993; 80: 1445 9.
  • 14
    Kmiot WA, Hesslewood SR, Smith N, et al. Evaluation of the inflammatory infiltrate in pouchitis with 111indium-labeled granulocytes. Gastroenterology 1993; 104: 981 8.
  • 15
    Miglioli M. Topical administration of 5-aminosalicylic acid: a therapeutic proposal for the treatment of pouchitis. N Engl J Med 1992; 320: 257257.
  • 16
    Tremaine WJ, Sandborn WJ, Phillips SF, et al. Mayo Clinic. Short chain fatty acid (SCFA) enema therapy for treatment-resistant pouchitis following ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC). Gastroenterology 1994; 106: A784A784(Abstract).
  • 17
    Gionchetti P, Rizzello F, Venturi A, et al. Long-term efficacy of bismuth carbomer enemas in patients with treatment-resistant chronic pouchitis. Aliment Pharmacol Ther 1997; 11: 673 8.
  • 18
    Tremaine WJ, Sandborn WJ, Wolff BG, et al. Bismuth carbomer foam enemas for active chronic pouchitis: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther 1997; 11: 1041 6.
  • 19
    Venturini AP & Marchi E. In vitro and in vivo evaluation of L/105, a new topical intestinal rifamycin. Chemioterapia 1986; 5: 257 62.
  • 20
    Hoover WW, Gerlach EH, Hoban DJ, et al. Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivate. Diagn Microbiol Infect Dis 1993; 16: 111 8.
  • 21
    Gillis JC & Brogden RN. Rifaximin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995; 49: 467 84.
  • 22
    Rizzello F, Gionchetti P, Venturi A, et al. Rifaximin systemic absorption in patients with ulcerative colitis. Eur J Clin Pharmacol 1998; 54: 91 3.
  • 23
    Gionchetti P, Rizzello F, Ferrieri A, et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig Dis Sci 1998; in press.
  • 24
    Brumfitt W, Franklin I, Grady D, et al. Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrob Agents Chemother 1984; 26: 757 61.
  • 25
    Goodman LJ, Kaplan RL, Petrak RM, et al. Effects of erythromycin and ciprofloxacin on chronic fecal excretion of Campylobacter species in marmosets. Antimicrob Agents Chemother 1986; 29: 185 7.
  • 26
    Colombel JF, Lemann M, Cassagnou M, et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Gastroenterology 1997; 112: A951A951(Abstract).
  • 27
    Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996; 91: 328 32.